DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
ZZFIRST
First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
PROSTATE
ESMO
2024
CALADRIO
Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
Breast
(Journal) Microbiome Research Reports
2024
METALLICA
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
BREAST
(Journal) eClinical Medicine
2024
DEBBRAH
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
BREAST
(Journal) Neuro-Oncology
2023
I3LUNG
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
LUNG
(Journal) Clinical Lung Cancer
2023
PHERGAIN
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)
BREAST
ASCO
2023
DEBBRAH
Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced
Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis:
Results from Cohort 5 of the DEBBRAH Study
BREAST
SABCS
2023
LUPER
Lurbinectedin In Combination With Pembrolizumab In Relapsed Small Cell Lung Cancer (SCLC): The Phase 1/2 LUPER Study
LUNG
ESMO
2023
ORPHEUS
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS
PENILE
ASCO
2023
PHERGAIN (sub-study)
Validation of a genomic assay in early-stage HER2+ breast cancer treated with trastuzumab and pertuzumab (HP): a correlative analysis from PHERGain phase II trial
BREAST
ESMO
2023
ATRACTIB
Efficacy and safety of first-line atezolizumab, bevacizumab, and paclitaxel in
patients with advanced triple-negative breast cancer (aTNBC):
the ATRACTIB phase II trial.
BREAST
SABCS
2023
PARSIFAL
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
BREAST
(Journal) The Oncologist
2023
Other MEDSIR related articles
